Stockreport
3 Things In Biotech, April 1: Fate's Omens, Mallinckrodt's Trial, Insmed's Journey [Seeking Alpha]
Last insmed earnings: 2/23 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations: investor.insmed.com
PDF
3 Things In Biotech, April 1: Fate's Omens, Mallinckrodt's Trial, Insmed's JourneySummaryFate Therapeutics shows early promise in ovarian cancer.Mallinckrodt on deck for its hyperbilirubinemia drug.Insmed demands its day with the FDA.
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | INSM | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
INSM alerts
INSM alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting INSMED news events
Weekly update
A roundup of the hottest topics
INSM
NEWS
NEWS
- Insmed to Host First Quarter 2018 Financial Results Conference Call on Wednesday, May 2, 2018[GlobeNewswire]
- Insmed, Inc. (NASDAQ: INSM) was upgraded by analysts at Credit Suisse Group AG from a "neutral" rating to an "outperform" rating. They now have a $31.00 price target on the stock.[MarketBeat]
- Insmed, Inc. (NASDAQ: INSM) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating.[MarketBeat]
- Insmed, Inc. (NASDAQ: INSM) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating.[MarketBeat]
- Insmed files U.S. marketing application for inhaled amikacin for type of lung disease; shares up 2% [Seeking Alpha][Seeking Alpha]
- More
INSM
SEC Filings
SEC Filings
- 4/5/18 - Form DEFA14A
- 4/5/18 - Form DEF
- 3/29/18 - Form 8-K
- INSM's page on the SEC website
- More